Leerink, Gilead Sciences
Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II trials, following promising ...
Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...
Donald Trump showed up for his quick shift at McDonald's in Feasterville ready to take orders at the drive-thru.
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
Morgan Stanley notes that Gilead (GILD) and Arcellx’s (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / ...
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...
Barchart on MSN1d
Gilead Sciences’ Quarterly Earnings Preview: What You Need to KnowGilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback